Title: EAU: Cialis (IC351) Improves Sexual Function In Diabetic Men With Erectile Dysfunction
URL: http://www.pslgroup.com/dg/1F73FE.htm
Doctor's Guide
April 6, 2001

Cialis

TORONTO, ON -- April 6, 2001 -- The first Phase 3 study for IC351 (Cialis™), a new PDE5 inhibitor being developed by Lilly ICOS LLC to treat erectile dysfunction (ED), showed strong results among one of the most difficult to treat populations of men with ED. The findings-to be released tomorrow at the European Association of Urology Meeting (EAU)-demonstrated that 64 percent of men with diabetes-related ED taking IC351 20 mg on-demand reported improved erections. This Cialis rate of response is considered high given the difficulties associated with treating diabetes-related ED.

"The impairment of the nerves and blood vessels that accompanies diabetes makes ED prevalent and particularly difficult to treat in this population," said Dr. Gerald Brock, a urologist from St. Joseph's Health Centre in London, Ontario. "This study, alongside previously released data, suggests that on-demand Cialis may help most men with ED regain sexual function, regardless of cause or severity."

Full article in http://www.docguide.com/dg.nsf/PrintPrint/14F3596C07327E0785256A2600526889

BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 31, 2001--ICOS Corporation (Nasdaq:ICOS) announced today that the New Drug Application (NDA) for Cialis(TM) has been accepted for review by the U.S. Food and Drug Administration. "Even though it was stated in our last quarterly conference call, that we probably would not make an announcement, several of our shareholders have made inquiries and therefore, we decided to make this release," stated Lacy Fitzpatrick, Associate Director of Investor Relations.